Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 26;17:9773–9793. doi: 10.2147/JIR.S483977

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The relationship between CXCL13 and the efficacy of immunotherapy. UMAP visualization of the major cell subsets of ovarian cancer (A) and the distribution of CXCL13 in different cells (B) in single-cell analysis of the GSE149614 database. (C) The proportion of different cell populations in ovarian cancer and normal tissue.(D) The relationship between CXCL13 and PD-L1.(E) The survival curve shows the prognostic differences caused by different expressions of CXCL13. Different CXCL13 expression groups lead to different clinical responses (F) and immune infiltration (G) differences in anti-PD-L1 therapy.